Bringing a veterinary product to market requires demonstrating that the product is not only effective, but also safe for the animals it is intended to treat. Central to that demonstration is the Target Animal Safety (TAS) study, a required component of nearly every New Animal Drug Application (NADA) submitted to the FDA’s Center for Veterinary Medicine (CVM).
While sponsors often focus on efficacy or manufacturing, underestimating the importance of TAS studies can delay development, trigger additional testing, or result in an incomplete regulatory submission. In this article, we explore the purpose, structure, and best practices for conducting Target Animal Safety studies that meet FDA expectations and supports a successful approval.
What Is a Target Animal Safety Study?
A Target Animal Safety (TAS) study is designed to evaluate the safety of a veterinary drug when administered at or above the intended use levels to the species for which the product is intended. These studies are typically conducted under controlled conditions and are meant to:
- Identify any dose-related adverse effects
- Determine a margin of safety
- Support appropriate label claims, including dosage and warnings
- Inform risk-benefit assessments for approval
TAS studies are not optional—they are a core regulatory requirement under 21 CFR Part 514 for all new animal drugs.
When Are TAS Studies Required?
TAS studies are typically required when:
- Submitting a NADA for a new chemical entity or new use
- Adding a new species or age group to an existing label
- Changing the route of administration or dosage form
- Pursuing conditional approvals
Even for generic products under an Abbreviated NADA (ANADA), TAS studies may be required if there are significant formulation changes from the reference drug.
Study Design and Key Elements
TAS studies must be tailored to the target species, formulation, and route of administration, but most follow a similar core structure:
- Controlled environment: Typically conducted in at companies that specialize in TAS studies.
- Multiple dose groups: Includes a control group that does not receive drug, the intended dose (1X), plus dose groups at higher multiples of the use dose, usually3x, and 5x
- Duration: Three times the expected duration of use, usually capped at 6 months for drugs that will be used chronically
- Endpoints: Focus on clinical signs, behavior, body weight, food intake, hematology, clinical chemistry, necropsy, and histopathology
- GLP Compliance: TAS studies are typically conducted under Good Laboratory Practice (GLP) standards
FDA expects the studies to provide a clear margin of safety that supports label recommendations and mitigates concerns related to overdosing, accidental exposure, or extended use. Side effects may be seen at higher doses, which helps vets and producers understand what to look for when the product is in use in the clinic or farm.
Practical Challenges for Sponsors
Sponsors new to veterinary drug development often underestimate the cost, time, and regulatory weight TAS studies carry. Common pitfalls include:
- Designing studies without FDA feedback (leading to rework)
- Using non-GLP facilities without justification
- Failing to replicate the final formulation or delivery method
- Failing to use drug batches manufactured the same way as the final product
- Overlooking the need for species-specific endpoints, especially in less common species
Early communication with CVM under an INAD is strongly encouraged. The agency will review protocols and help ensure the design is acceptable before initiation.
How TAS Studies Fit Into the Broader Approval Process
TAS data forms one of the key technical sections of a NADA. Along with effectiveness, CMC, and environmental safety, the TAS section is critical to the overall benefit-risk analysis performed by CVM.
A strong TAS study not only satisfies FDA requirements—it can also support commercial confidence, reduce post-approval liability, and build trust with veterinarians and livestock producers.
DSI's Role in Target Animal Safety Strategy
DS Inpharmatics supports sponsors by:
- Developing and submitting TAS protocols under INAD
- Managing CVM communications and feedback
- Identifying appropriate CROs or academic partners
- Ensuring GLP compliance and proper data reporting
- Integrating TAS findings into the NADA submission package
Whether you're working with companion animals, food-producing species, or exotics, our team ensures your TAS studies are scientifically sound and regulatory-ready.
Final Thoughts
Target Animal Safety studies are more than a regulatory hurdle—they are an essential part of demonstrating product quality and commitment to animal welfare. Properly designed and executed, TAS studies help sponsors advance products with confidence and clarity.
Need help planning your TAS study or managing your INAD strategy?
The veterinary regulatory experts at DSI are here to help. Reach out today to align your development strategy with CVM expectations and accelerate your path to approval.
